Antibe Therapeutics Announces Additional Validation Data on ATB-346

TORONTO-- Antibe Therapeutics Inc. (“Antibe” or the “Company”) (ATE.V) announced today the results of additional testing of the in vivo activity of its lead anti-inflammatory drug, ATB-346.

The results support the Company's earlier communication that ATB-346 may be effective at much lower doses than previously expected, and that once daily dosing may be effective. Together, over 600 blood samples from its Phase 1 human clinical trial were independently analysed to assess the ability of ATB-346, at doses ranging from 25 to 1000 mg, to inhibit the enzyme "cyclooxygenase" (COX). The reduction of pain and inflammation by non-steroidal anti-inflammatory drugs (NSAIDs) is attributed to their ability to inhibit COX activity.

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Malignant Gliomas

CALGARY, April 17, 2015  - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN^®, for the treatment of malignant glioma.  The Company applied for an ODD for pediatric high grade gliomas (HGG), however the FDA granted an ODD for the broader indication of malignant glioma in patients of all ages.  In three previous brain cancer studies including gliomas, REOLYSIN^® has been shown to infect a variety of brain tumors when delivered intravenously.

22nd Century Group Announces Launch of “0.0 mg Nicotine” MAGIC Cigarettes in Spain

CLARENCE, N.Y.-- 22nd Century Group, Inc. (NYSE MKT:XXII) today announced that on April 21, 2015 in Valencia, Spain at the SH Valencia Palace hotel, the Company will hold a press conference announcing the launch of MAGIC cigarettes in approximately 900 state-licensed retail shops across Spain. MAGIC cigarettes will be available to consumers starting April 24, 2015.

22nd Century’s MAGIC cigarettes are made with the Company’s proprietary very low nicotine tobacco and are manufactured for sale in Europe by Orion Tobacco Corporation. Designed to appeal to discriminating consumers and positioned to compete with premium cigarette brands, MAGIC 0 yields only 0.04 mg nicotine per cigarette – 95% less nicotine than conventional cigarette brands. Indeed, MAGIC 0 is the world’s only virtually nicotine-free tobacco cigarette. MAGIC 2 yields 0.2 mg nicotine per cigarette – an 80% reduction in nicotine as compared to conventional brands.